B. Riley Securities Reiterates Buy on Microbot Medical, Lowers Price Target to $4

Benzinga Newsdesk www.benzinga.com Negative 82.8%

Neg 82.8% Neu 0% Pos 0%

B. Riley Securities analyst Anderson Schock reiterates Microbot Medical (NASDAQ:MBOT) with a Buy and lowers the price target from $5 to $4.